A pilot study of 12 patients with BRAF V600E-mutant, RAI-refractory thyroid cancer demonstrated that 4 out of 10 evaluable patients exhibited increased iodine uptake on iodine-124 PET scans, leading to therapeutic I-131 administration and tumor regressions at 6 months (52). The gene discussed is BRAF; the disease is thyroid cancer.